138 related articles for article (PubMed ID: 37844755)
61. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.
Tavori H; Fan D; Blakemore JL; Yancey PG; Ding L; Linton MF; Fazio S
Circulation; 2013 Jun; 127(24):2403-13. PubMed ID: 23690465
[TBL] [Abstract][Full Text] [Related]
62. Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol.
Spolitu S; Okamoto H; Dai W; Zadroga JA; Wittchen ES; Gromada J; Ozcan L
Circ Res; 2019 Jan; 124(1):38-51. PubMed ID: 30582457
[TBL] [Abstract][Full Text] [Related]
63. Curcumin nicotinate decreases serum LDL cholesterol through LDL receptor-mediated mechanism.
Zhang C; Xiang D; Zhao Q; Jiang S; Wang C; Yang H; Huang Y; Yuan Y; Liu X; Huang Z; Zeng Y; Wen H; Long S; Hao H; Tuo Q; Liu Z; Liao D
Eur J Pharmacol; 2022 Sep; 931():175195. PubMed ID: 35964656
[TBL] [Abstract][Full Text] [Related]
64. Deferoxamine stimulates LDLR expression and LDL uptake in HepG2 cells.
Guillemot J; Asselin MC; Susan-Resiga D; Essalmani R; Seidah NG
Mol Nutr Food Res; 2016 Mar; 60(3):600-8. PubMed ID: 26577249
[TBL] [Abstract][Full Text] [Related]
65. The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression.
Miranda MX; van Tits LJ; Lohmann C; Arsiwala T; Winnik S; Tailleux A; Stein S; Gomes AP; Suri V; Ellis JL; Lutz TA; Hottiger MO; Sinclair DA; Auwerx J; Schoonjans K; Staels B; Lüscher TF; Matter CM
Eur Heart J; 2015 Jan; 36(1):51-9. PubMed ID: 24603306
[TBL] [Abstract][Full Text] [Related]
66. Artificial Platelets for Efficient siRNA Delivery to Clear "Bad Cholesterol".
Zhang Y; Qin Y; Li H; Peng Q; Wang P; Yang L; Chen S; Li M; Fu J; Yu X; Zhang L
ACS Appl Mater Interfaces; 2020 Jun; 12(25):28034-28046. PubMed ID: 32469502
[TBL] [Abstract][Full Text] [Related]
67. Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C.
Li S; Zhao X; Zhang Y; Zhu CG; Guo YL; Wu NQ; Xu RX; Qing P; Gao Y; Sun J; Liu G; Dong Q; Li JJ
Oncotarget; 2017 Feb; 8(7):12333-12341. PubMed ID: 27713142
[TBL] [Abstract][Full Text] [Related]
68. Delineation of molecular pathways that regulate hepatic PCSK9 and LDL receptor expression during fasting in normolipidemic hamsters.
Wu M; Dong B; Cao A; Li H; Liu J
Atherosclerosis; 2012 Oct; 224(2):401-10. PubMed ID: 22954675
[TBL] [Abstract][Full Text] [Related]
69. Inhibition of Proprotein Convertase Subtilisin/Kexin Type 9 Ameliorates Liver Fibrosis via Mitigation of Intestinal Endotoxemia.
Zou Y; Li S; Xu B; Guo H; Zhang S; Cai Y
Inflammation; 2020 Feb; 43(1):251-263. PubMed ID: 31776890
[TBL] [Abstract][Full Text] [Related]
70. Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond.
Grewal T; Buechler C
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162992
[TBL] [Abstract][Full Text] [Related]
71. microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production.
Dong J; He M; Li J; Pessentheiner A; Wang C; Zhang J; Sun Y; Wang WT; Zhang Y; Liu J; Wang SC; Huang PH; Gordts PL; Yuan ZY; Tsimikas S; Shyy JY
JCI Insight; 2020 Dec; 5(23):. PubMed ID: 33119548
[TBL] [Abstract][Full Text] [Related]
72. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
[TBL] [Abstract][Full Text] [Related]
73. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
74. Curcumin Protects Against Intestinal Origin Endotoxemia in Rat Liver Cirrhosis by Targeting PCSK9.
Cai Y; Lu D; Zou Y; Zhou C; Liu H; Tu C; Li F; Liu L; Zhang S
J Food Sci; 2017 Mar; 82(3):772-780. PubMed ID: 28196290
[TBL] [Abstract][Full Text] [Related]
75. Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome.
Olaniyi KS; Areloegbe SE; Areola ED; Sabinari IW; Fafure AA; Agbana RD; Atuma CL; Shah MZUH; Ajadi IO; Olatunji LA
Toxicol Appl Pharmacol; 2023 Aug; 473():116604. PubMed ID: 37328115
[TBL] [Abstract][Full Text] [Related]
76. Proteinuria converts hepatic heparan sulfate to an effective proprotein convertase subtilisin kexin type 9 enzyme binding partner.
Shrestha P; Yazdani S; Vivès RR; El Masri R; Dam W; van de Sluis B; van den Born J
Kidney Int; 2021 Jun; 99(6):1369-1381. PubMed ID: 33609572
[TBL] [Abstract][Full Text] [Related]
77. Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).
Ben Djoudi Ouadda A; Gauthier MS; Susan-Resiga D; Girard E; Essalmani R; Black M; Marcinkiewicz J; Forget D; Hamelin J; Evagelidis A; Ly K; Day R; Galarneau L; Corbin F; Coulombe B; Çaku A; Tagliabracci VS; Seidah NG
Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):1996-2013. PubMed ID: 31553664
[TBL] [Abstract][Full Text] [Related]
78. Hydrogen sulfide inhibits PCSK9 expression through the PI3K/Akt‑SREBP‑2 signaling pathway to influence lipid metabolism in HepG2 cells.
Xiao J; Bai XQ; Liao L; Zhou M; Peng J; Xiang Q; Ren Z; Wen HY; Jiang ZS; Tang ZH; Wang MM; Liu LS
Int J Mol Med; 2019 May; 43(5):2055-2063. PubMed ID: 30864739
[TBL] [Abstract][Full Text] [Related]
79. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.
Seidah NG; Prat A; Pirillo A; Catapano AL; Norata GD
Cardiovasc Res; 2019 Mar; 115(3):510-518. PubMed ID: 30629143
[TBL] [Abstract][Full Text] [Related]
80. New Loss-of-Function Mutations in PCSK9 Reduce Plasma LDL Cholesterol.
Meng FH; Liu S; Xiao J; Zhou YX; Dong LW; Li YF; Zhang YQ; Li WH; Wang JQ; Wang Y; Song BL; Ma YT; Fu ZY; Luo J
Arterioscler Thromb Vasc Biol; 2023 Jul; 43(7):1219-1233. PubMed ID: 37165876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
